Polyrizon Ltd. announced today that its PL‑14 Allergy Blocker has shown encouraging efficacy in a pre‑clinical study. The study tested the hydrogel barrier against Der p 1, a major house dust mite allergen, and found that PL‑14 limited allergen diffusion over time, forming an effective nasal barrier. The allergen load used was estimated to be tens of times higher than typical real‑world exposure levels, underscoring the robustness of the barrier.
CEO Tomer Izraeli said the results reinforce PL‑14’s potential as a frontline preventive solution for allergic rhinitis and other nasal allergies. He highlighted that the Capture & Contain platform is designed to capture and contain airborne allergens before they reach the nasal mucosa. The company plans to use these findings to support the initiation of clinical studies and regulatory pathways for PL‑14 and other candidates.
According to a Future Market Insights report, the allergy immunotherapy market is projected to grow from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, expanding at a CAGR of 7.9 %. Polyrizon’s technology could tap into this expanding market by offering a non‑invasive, barrier‑forming alternative to existing treatments. The positive pre‑clinical data provide a critical step toward advancing PL‑14 toward clinical trials and eventual commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.